Cargando…

Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa

BACKGROUND: Developing African countries face health problems that they struggle to solve. The major causes of this situation are high therapeutic and logistical costs. Plant-made therapeutics are easy to produce due to the lack of the safety considerations associated with traditional fermenter-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamogo, Pingdwende Kader Aziz, Brugidou, Christophe, Sérémé, Drissa, Tiendrébéogo, Fidèle, Djigma, Florencia Wendkuuni, Simpore, Jacques, Lacombe, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937724/
https://www.ncbi.nlm.nih.gov/pubmed/31888686
http://dx.doi.org/10.1186/s12985-019-1263-0
_version_ 1783483921602707456
author Bamogo, Pingdwende Kader Aziz
Brugidou, Christophe
Sérémé, Drissa
Tiendrébéogo, Fidèle
Djigma, Florencia Wendkuuni
Simpore, Jacques
Lacombe, Séverine
author_facet Bamogo, Pingdwende Kader Aziz
Brugidou, Christophe
Sérémé, Drissa
Tiendrébéogo, Fidèle
Djigma, Florencia Wendkuuni
Simpore, Jacques
Lacombe, Séverine
author_sort Bamogo, Pingdwende Kader Aziz
collection PubMed
description BACKGROUND: Developing African countries face health problems that they struggle to solve. The major causes of this situation are high therapeutic and logistical costs. Plant-made therapeutics are easy to produce due to the lack of the safety considerations associated with traditional fermenter-based expression platforms, such as mammalian cells. Plant biosystems are easy to scale up and inexpensive, and they do not require refrigeration or a sophisticated medical infrastructure. These advantages provide an opportunity for plant-made pharmaceuticals to counteract diseases for which medicines were previously inaccessible to people in countries with few resources. MAIN BODY: The techniques needed for plant-based therapeutic production are currently available. Viral expression vectors based on plant viruses have greatly enhanced plant-made therapeutic production and have been exploited to produce a variety of proteins of industrial, pharmaceutical and agribusiness interest. Some neglected tropical diseases occurring exclusively in the developing world have found solutions through plant bioreactor technology. Plant viral expression vectors have been reported in the production of therapeutics against these diseases occurring exclusively in the third world, and some virus-derived antigens produced in plants exhibit appropriate antigenicity and immunogenicity. However, all advances in the use of plants as bioreactors have been made by companies in Europe and America. The developing world is still far from acquiring this technology, although plant viral expression vectors may provide crucial help to overcome neglected diseases. CONCLUSION: Today, interest in these tools is rising, and viral amplicons made in and for Africa are in progress. This review describes the biotechnological advances in the field of plant bioreactors, highlights factors restricting access to this technology by those who need it most and proposes a solution to overcome these limitations.
format Online
Article
Text
id pubmed-6937724
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69377242019-12-31 Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa Bamogo, Pingdwende Kader Aziz Brugidou, Christophe Sérémé, Drissa Tiendrébéogo, Fidèle Djigma, Florencia Wendkuuni Simpore, Jacques Lacombe, Séverine Virol J Review BACKGROUND: Developing African countries face health problems that they struggle to solve. The major causes of this situation are high therapeutic and logistical costs. Plant-made therapeutics are easy to produce due to the lack of the safety considerations associated with traditional fermenter-based expression platforms, such as mammalian cells. Plant biosystems are easy to scale up and inexpensive, and they do not require refrigeration or a sophisticated medical infrastructure. These advantages provide an opportunity for plant-made pharmaceuticals to counteract diseases for which medicines were previously inaccessible to people in countries with few resources. MAIN BODY: The techniques needed for plant-based therapeutic production are currently available. Viral expression vectors based on plant viruses have greatly enhanced plant-made therapeutic production and have been exploited to produce a variety of proteins of industrial, pharmaceutical and agribusiness interest. Some neglected tropical diseases occurring exclusively in the developing world have found solutions through plant bioreactor technology. Plant viral expression vectors have been reported in the production of therapeutics against these diseases occurring exclusively in the third world, and some virus-derived antigens produced in plants exhibit appropriate antigenicity and immunogenicity. However, all advances in the use of plants as bioreactors have been made by companies in Europe and America. The developing world is still far from acquiring this technology, although plant viral expression vectors may provide crucial help to overcome neglected diseases. CONCLUSION: Today, interest in these tools is rising, and viral amplicons made in and for Africa are in progress. This review describes the biotechnological advances in the field of plant bioreactors, highlights factors restricting access to this technology by those who need it most and proposes a solution to overcome these limitations. BioMed Central 2019-12-30 /pmc/articles/PMC6937724/ /pubmed/31888686 http://dx.doi.org/10.1186/s12985-019-1263-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Bamogo, Pingdwende Kader Aziz
Brugidou, Christophe
Sérémé, Drissa
Tiendrébéogo, Fidèle
Djigma, Florencia Wendkuuni
Simpore, Jacques
Lacombe, Séverine
Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title_full Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title_fullStr Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title_full_unstemmed Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title_short Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
title_sort virus-based pharmaceutical production in plants: an opportunity to reduce health problems in africa
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937724/
https://www.ncbi.nlm.nih.gov/pubmed/31888686
http://dx.doi.org/10.1186/s12985-019-1263-0
work_keys_str_mv AT bamogopingdwendekaderaziz virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT brugidouchristophe virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT seremedrissa virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT tiendrebeogofidele virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT djigmaflorenciawendkuuni virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT simporejacques virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica
AT lacombeseverine virusbasedpharmaceuticalproductioninplantsanopportunitytoreducehealthproblemsinafrica